Biogen (NASDAQ:BIIB) Shares Break Above 200 Day Moving Average - Should You Sell?

Key Points

• Biogen shares broke above their 200-day moving average, reaching $223.85 and last trading near $223.59, compared with the 200-day average of $201.28.
• Analyst sentiment remains favorable, with an overall “Moderate Buy” rating and an average price target of $230.14; recent targets range from $215 to $300.
• Biogen exceeded quarterly expectations with EPS of $3.60 versus the $2.94 consensus and revenue of $2.74 billion, while institutional investors own approximately 87.93% of the stock.

Biogen Inc. (NASDAQ:BIIB - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $201.28 and traded as high as $223.85. Biogen shares last traded at $223.59, with a volume of 951,296 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BIIB shares. UBS Group increased their target price on Biogen from $225.00 to $240.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Guggenheim boosted their target price on shares of Biogen from $260.00 to $280.00 and gave the company a "buy" rating in a research note on Tuesday, July 21st. Jefferies Financial Group restated a "buy" rating on shares of Biogen in a research note on Monday, July 13th. Citigroup raised their price target on Biogen from $200.00 to $215.00 and gave the company a "neutral" rating in a research note on Monday, August 3rd. Finally, Oppenheimer reissued an "outperform" rating and set a $300.00 price objective on shares of Biogen in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Biogen has an average rating of "Moderate Buy" and an average price target of $230.14.

Biogen Price Performance

The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The company has a market cap of $33.04 billion, a PE ratio of 39.57, a price-to-earnings-growth ratio of 2.43 and a beta of 0.09. The stock has a 50 day moving average of $216.14 and a 200-day moving average of $201.28.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts' consensus estimates of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.Biogen's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts predict that Biogen Inc. will post 12.41 earnings per share for the current year.

Hedge Funds Weigh In On Biogen

Several institutional investors have recently made changes to their positions in BIIB. Polaris Financial Partners acquired a new position in shares of Biogen in the third quarter worth about $109,000. Boltwood Capital Management boosted its stake in Biogen by 33.1% during the 3rd quarter. Boltwood Capital Management now owns 1,982 shares of the biotechnology company's stock worth $448,000 after purchasing an additional 493 shares during the last quarter. QRG Capital Management Inc. boosted its position in Biogen by 47.9% during the second quarter. QRG Capital Management Inc. now owns 48,819 shares of the biotechnology company's stock worth $10,548,000 after acquiring an additional 15,817 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its position in shares of Biogen by 20.5% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 1,738 shares of the biotechnology company's stock valued at $376,000 after purchasing an additional 296 shares in the last quarter. Finally, Tidal Investments LLC grew its holdings in Biogen by 9.0% in the 2nd quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company's stock valued at $13,794,000 after buying an additional 5,256 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen's products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich's ataxia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.